Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
5,946 | Dovepress* | 5,515+ | 1,159 | 6,674 | |
PubMed Central* | 431 | 230 | 661 | ||
Totals | 5,946 | 1,389 | 7,335 | ||
*Since 30 June 2016 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
3 | 0 | 0 | 0 | 1 | 2 |
View citations on PubMed Central and Google Scholar